熱門資訊> 正文

Genmat确认第一季度DARZAFLEX销售额为396亿美元，由美国需求主导

2026-04-14 20:01

Genmab (GMAB) said that worldwide net sales of its multiple myeloma therapy DARZALEX (daratumumab) as reported by Johnson & Johnson (JNJ), totaled $3.96B in Q1.
U.S. sales came in at $2.208B, while $1.756B was generated from international markets.
Sales include both the intravenous formulation and the subcutaneous version, marketed in the U.S. as DARZALEX FASPRO.
GMAB (GMAB) stock traded ~2% higher on Tuesday during pre-market hours of trading.

More on Genmab

Genmab: Multiple Binaries Could Alter The Thesis
Genmab A/S (GMAB) Presents at Barclays 28th Annual Global Healthcare Conference Transcript
Genmab A/S (GMAB) Presents at Leerink Global Healthcare Conference 2026 Transcript
Most oversold healthcare stocks above $10B on Wall Street amid Middle East disruptions
Genmab down after trial data for AbbVie-partnered Epkinly in B-cell lymphoma

推薦文章

風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。